| 001 | 182138 | ||
| 005 | 20240229145710.0 | ||
| 024 | 7 | _ | |a 10.1111/tan.14846 |2 doi |
| 024 | 7 | _ | |a pmid:36251018 |2 pmid |
| 024 | 7 | _ | |a 0001-2815 |2 ISSN |
| 024 | 7 | _ | |a 1399-0039 |2 ISSN |
| 024 | 7 | _ | |a 2059-2302 |2 ISSN |
| 024 | 7 | _ | |a 2059-2310 |2 ISSN |
| 024 | 7 | _ | |a altmetric:137318992 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-02455 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Witt, Johannes |0 0000-0001-6648-8828 |b 0 |e First author |
| 245 | _ | _ | |a A simple approach for detecting HLA-A*02 alleles in archival formalin-fixed paraffin-embedded tissue samples and an application example for studying cancer immunoediting. |
| 260 | _ | _ | |a Oxford |c 2023 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1671027646_24789 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:F210#LA:F210# / 2023 Jan;101(1):24-33 |
| 520 | _ | _ | |a The human leukocyte antigen (HLA) system represents a central component of the antigen presentation machinery. As every patient possesses a defined set of HLA molecules, only certain antigens can be presented on the cell surface. Thus, studying HLA type-dependent antigen presentation can improve the understanding of variation in susceptibility to various diseases, including infectious diseases and cancer. In archival formalin-fixed paraffin-embedded (FFPE) tissue, the HLA type is difficult to analyze due to fragmentation of DNA, hindering the application of commonly used assays that rely on long DNA stretches. Addressing these difficulties, we present a refined approach for characterizing presence or absence of HLA-A*02, the most common HLA-A allele in the Caucasian population, in archival samples. We validated our genotyping strategy in a cohort of 90 samples with HLA status obtained by an NGS-based method. 90% (n=81) of the samples could be analyzed with the approach. For all of them, the presence or absence of HLA-A*02 alleles was correctly determined with the method, demonstrating 100% sensitivity and specificity (95% CI: 91.40 to 100% and 91.19 to 100%). Furthermore, we provide an example of application in an independent cohort of 73 FFPE microsatellite-unstable (MSI) colorectal cancer samples. As MSI cancer cells encompass a high number of mutations in coding microsatellites (cMS), leading to the generation of highly immunogenic frameshift peptide (FSP) antigens, they are ideally suited for studying relations between the mutational landscape of tumor cells and interindividual differences in the immune system, including the HLA genotype. Overall, our method can help to promote studying HLA type-dependency during the pathogenesis of a wide range of diseases, making archival and historic tissue samples accessible for identifying HLA-A*02 alleles. This article is protected by copyright. All rights reserved. |
| 536 | _ | _ | |a 316 - Infektionen, Entzündung und Krebs (POF4-316) |0 G:(DE-HGF)POF4-316 |c POF4-316 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Cancer immunoediting |2 Other |
| 650 | _ | 7 | |a Formalin-fixed paraffin-embedded tissue samples |2 Other |
| 650 | _ | 7 | |a HLA typing |2 Other |
| 650 | _ | 7 | |a MSI cancer |2 Other |
| 700 | 1 | _ | |a Haupt, Saskia |b 1 |
| 700 | 1 | _ | |a Ahadova, Aysel |0 P:(DE-He78)07eef6d38a91f4642c810745c5bf5000 |b 2 |u dkfz |
| 700 | 1 | _ | |a Bohaumilitzky, Lena |0 P:(DE-He78)a7f54298fcba548e34453b02202e6519 |b 3 |u dkfz |
| 700 | 1 | _ | |a Fuchs, Vera |0 P:(DE-He78)bf22847e1e57b38a1cac0e03d63dbdec |b 4 |u dkfz |
| 700 | 1 | _ | |a Ballhausen, Alexej |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Przybilla, Moritz Jakob |0 P:(DE-He78)2c6d4f81ba6891f170d25801c181ace1 |b 6 |u dkfz |
| 700 | 1 | _ | |a Jendrusch, Michael |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Seppälä, Toni T |b 8 |
| 700 | 1 | _ | |a Fürst, Daniel |0 0000-0001-9542-3169 |b 9 |
| 700 | 1 | _ | |a Walle, Thomas |b 10 |
| 700 | 1 | _ | |a Busch, Elena |b 11 |
| 700 | 1 | _ | |a Haag, Georg Martin |0 P:(DE-He78)f54d0426f2215c539d3a7ae1b400b57d |b 12 |u dkfz |
| 700 | 1 | _ | |a Hüneburg, Robert |b 13 |
| 700 | 1 | _ | |a Nattermann, Jacob |b 14 |
| 700 | 1 | _ | |a von Knebel Doeberitz, Magnus |0 P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f |b 15 |u dkfz |
| 700 | 1 | _ | |a Heuveline, Vincent |b 16 |
| 700 | 1 | _ | |a Kloor, Matthias |0 P:(DE-He78)028ee60cca729028708496826f077b58 |b 17 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1111/tan.14846 |g p. tan.14846 |0 PERI:(DE-600)2844321-4 |n 1 |p 24-33 |t HLA |v 101 |y 2023 |x 0001-2815 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:182138 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 0000-0001-6648-8828 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)07eef6d38a91f4642c810745c5bf5000 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)a7f54298fcba548e34453b02202e6519 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)bf22847e1e57b38a1cac0e03d63dbdec |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)2c6d4f81ba6891f170d25801c181ace1 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)f54d0426f2215c539d3a7ae1b400b57d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 17 |6 P:(DE-He78)028ee60cca729028708496826f077b58 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-316 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Infektionen, Entzündung und Krebs |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2021-01-29 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-29 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-27 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b HLA : 2022 |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-27 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-27 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b HLA : 2022 |d 2023-10-27 |
| 920 | 2 | _ | |0 I:(DE-He78)F210-20160331 |k F210 |l KKE Angewandte Tumorbiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)F210-20160331 |k F210 |l KKE Angewandte Tumorbiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D120-20160331 |k D120 |l D120 Angewandte Tumor-Immunität |x 1 |
| 920 | 0 | _ | |0 I:(DE-He78)F210-20160331 |k F210 |l KKE Angewandte Tumorbiologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F210-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D120-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::